TRUE Private Wealth Advisors Has $576,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

TRUE Private Wealth Advisors lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 82.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,569 shares of the company’s stock after acquiring an additional 2,516 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Novo Nordisk A/S were worth $576,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Pacific Center for Financial Services grew its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares during the period. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. Citizens National Bank Trust Department raised its position in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after purchasing an additional 150 shares in the last quarter. Finally, Tyler Stone Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on NVO. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Trading Up 0.9 %

NVO opened at $124.55 on Thursday. The stock has a market cap of $558.92 billion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The company has a fifty day moving average of $126.28 and a 200-day moving average of $110.42.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.